Patent application number | Description | Published |
20090029907 | Recombinant Method for Production of an Erythropoiesis Stimulating Protein - The present invention relates to the recombinant method used for the production of a highly glycosylated form (in total five N linked glycosylations as opposed to three N linked glyosylations in the natural EPO) of erythropoietin. The added sites for glycosylation will result in greater number of carbohydrate chains, and higher sialic acid content than human EPO, which in turn would impart to the recombinant molecule a longer half-life. The invention further relates to the construction of expression cassettes comprising nucleic acid sequences encoding for the highly glycosylated form of Erythropoietin and stable expression in the host cells. The invention further relates to the optimized method for purification of the erythropoiesis stimulating protein. The recombinant EPO according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for an increase in the hematocrit for treatment of anemia and for restoration of patient well being and quality of life. | 01-29-2009 |
20090036356 | Octanoic acid derivatives as dipeptidyl peptidase inhibitors - The present invention is directed to novel Octanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of Octanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of Octanoic acid derivatives of the invention. | 02-05-2009 |
20090068721 | Process for the Production of Recombinant Activated Human Protein C for the Treatment of Sepsis - The present invention relates to a recombinant method of production of activated Protein C. The invention relates to a method of construction, transformation, expression, purification and production of recombinant activated human protein C. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells. | 03-12-2009 |
20090220520 | Recombinant method for the production of a monoclonal antibody to CD52 for the treatment of chronic lymphocytic leukemia - The present invention relates to the recombinant method used for the production of soluble form monoclonal antibody that binds to CD52. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD 52, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells. | 09-03-2009 |
20090285795 | Method for the Production of a Monoclonal Antibody to CD20 for the Treatment of B-Cell Lymphoma - The present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). The treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells. | 11-19-2009 |
20100129478 | Plant Extracts and Methods and Uses Therefore - The invention relates to compositions such as pharmaceutical compositions and comestibles comprising extracts of | 05-27-2010 |
20110064833 | SYNERGISTIC HERBAL COMPOSITION AND PROCESS OF PREPARATION THEREOF - The present invention relates to a synergistic herbal composition for diabetes and related disorders comprising extracts of plant | 03-17-2011 |
20110159118 | Screening Method (Metabolite Grid) for Therapeutic Extracts and Molecules for Diabetes - The present invention provides therapeutic compositions derived from plants useful for treating diabetes. The present invention also provides methods for screening plant metabolites and constituents to identify therapeutic agents and/or dietary supplements for treating diabetes. The therapeutic compositions can be derived from plants such as | 06-30-2011 |
20110190482 | POLYMER ENCAPSULATED ALUMINUM PARTICULATES - The present invention relates to use of novel bioinformatics approach for predicting and identifying Scaffold/Matrix attachment regions (S/MARs) from different genomic database. | 08-04-2011 |
20110231956 | Environmentally Adjusted Transgenic Plants - The present invention relates to a novel transgenic plant having tolerance to salt stress. The plant is transformed with a recombinant nucleic acid encoding glutamic acid decarboxylase isolated from | 09-22-2011 |
20110277188 | Change in Plant Architecture - The present invention relates to method for generating plants having altered architecture by introducing into plants, isolated nucleic acid molecules that can be used to produce transgenic plants characterized by altered plant architecture, carbon and nitrogen partitioning, enhanced biomass and or improved harvestable yield and to plants so generated and parts of these plants. More particularly, the present invention relates to a method for modifying a plant so as to produce a plant exhibiting an altered phenotype. Also provided are isolated nucleic sequence that encodes GAD polypeptide, vectors capable of expressing such nucleic acid molecules, host cells containing such vectors, and polypeptide encoded by such nucleic acids. | 11-10-2011 |
20120017334 | Nitrogen Use Efficient Transgenic Plants - The present invention relates to glutamate decarboxylase (GAD) gene sequence isolated from | 01-19-2012 |
Patent application number | Description | Published |
20090118371 | Delta 6 Desaturase From Thraustochytrid and its Uses Thereof - The present invention is directed to an isolated delta-6 desaturase gene from Schizochytrium. It is further directed to the cloning of delta-6 desaturase derived from Schizochytrium in Yeast. The nucleic acid sequence and the amino acid sequences of the delta-6 desaturase are disclosed. Further disclosed are the constructs, vector comprising the gene encoding the enzyme delta-6 desaturase in functional combination with the heterologous regulatory sequences. The novel delta-6 desaturase can be used in a metabolic pathway to convert linoleic acid to gamma linolenic acid (omega-6 pathway). The invention provides the identification, isolation of these novel nucleic acids from Schizochytrium that encode the above-mentioned proteins. The invention specifically exemplifies recombinant yeast cells harboring the vector comprising the delta-6 desaturase gene and by the virtue of the enzyme produced shall be able to produce gamnia-linolenic acid. | 05-07-2009 |
20090246188 | Method for Production of a Bioengineered Form of Tissue Plasminogen Activator - The present invention relates to the recombinant method used for the production of soluble form of human tissue plasminogen activator variant. In this variant the threonine at position 103 of the endogenous tissue plasminogen activator is replaced by an asparagine leading to a new glycosylation site. At position 117 of the endogenous tissue plasminogen activator asparagine has been replaced by glutamine, leading to the removal of an N linked glycosylation site. At position 296-299 the amino acids lysine, histidine, arginine, and arginine have been replaced by four alanine amino acids. The invention further relates to the de novo synthesis of the nucleic acid sequence encoding tissue plasminogen activator, transformation of the constructed nucleic acid sequences into competent bacteria and sub-cloning of the same into mammalian expression vectors for the expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest have been disclosed. The recombinant human tissue plasminogen activator, according to the invention, and the salts and functional derivatives thereof, may comprise the active ingredient of pharmaceutical compositions for treatment of treatment of heart attack and stroke patients. These compositions are yet another aspect of the present invention. | 10-01-2009 |
20090280196 | CISSUS QUADRANGULARIS PLANT EXTRACTS FOR TREATING OSTEOPOROSIS AND THE EXTRACTION PROCESS THEREOF - The invention relates to compositions and methods for preventing, treating, or managing osteoporosis or conditions which are characterized by increased bone resorption, comprising administration of a prophylactically and therapeutically effective amount of | 11-12-2009 |
20090288230 | Novel Efficient Transformation Method for Sunflower and Oil Seeds Based On Positive Selection - The invention describes a highly improved, reproducible and a consistent method of transformation and regeneration that results in obtaining 12-15% transgenic plants. The present invention relates to a method of selecting genetically transformed Sunflower explants based on their ability to utilize Xylose as a sole carbohydrate source. Further disclosed is the nucleic acid sequence of the Xylose Isomerase gene, vector construction for incorporation of the selection marker gene and the process of | 11-19-2009 |
20090317501 | Pinus Pinea Plant Extracts For Treating Osteoporosis and the Extraction Process Thereof - The present invention is concerned with nutritional or pharmaceutical compositions comprising extracts or concentrates of plants and the mixtures thereof belonging to | 12-24-2009 |
20100120103 | Recombinant Production Docosahexaenoic Acid (DHA) in Yeast - The present invention relates to a specifically novel recombinant method of production of the omega-3 fatty acid, Docosahexaenoic acid by a potentially safe recombinant organism | 05-13-2010 |
20100247638 | ORGANOLEPTICALLY IMPROVED DIETARY FIBER COMPOSITION AND A PROCESS THEREOF (TEESTAR) - The present invention is in relation to an organoleptically improved dietary fiber composition from | 09-30-2010 |
20110204222 | METHOD OF CHARACTERIZING PHYTOCHEMICALS FROM TRIGONELLA FOENUM GRACEUM - The present invention relates to identification and characterization of Phytochemicals and metabolites from | 08-25-2011 |
20120022017 | COMPOSITION AND A METHOD THEREOF - The present invention describes a palatable and orally administrable form of composition comprising proteins, galactomannans and base matrix optionally along with acceptable additives. | 01-26-2012 |